British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
Gordon W. Moran, Morris Gordon, Vassiliki Sinopolou, Shellie Radford, Ana-Maria Darie, Sudheer K. Vuyyuru, Laith Alrubaiy, Naila Arebi, Jonathan Blackwell, Thomas D. Butler, Thean S. Chew, Michael Colwill, Rachel Cooney, Gabriele De Marco, Said Din, Shahida Din, Roger Feakins, Marco Gasparetto, Hannah Gordon, Richard Hansen, Klaartje Kok, Aditi Kumar, Christopher A Lamb, Jimmy Limdi, Eleanor Liu, Maurice B Loughrey, Dennis McGonagle, Kamal Patel, Polychronis Pavlidis, Christian Selinger, Matthew Shale, Philip J Smith, Sreedhar Subramanian, Stuart A Taylor, Gloria Shwe Zin Tun, Ajay Mark Verma, Newton A C S Wong
Abstract
In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revised in 2019. These updated guidelines aim to complement the IBD standards and promote the use of the national primary care diagnostic pathway for lower gastrointestinal symptoms to enhance diagnostic accuracy and timeliness. Formulated through a systematic and transparent process, this document reflects a consensus of best practices based on current evidence. The guideline, while developed primarily for the UK, is structured to support IBD management internationally. It is endorsed by the BSG executive board and CSSC without external commercial funding, with involvement primarily supported through professional roles in public institutions and the National Health Service (NHS). Methodological revisions since the prior guidelines have enhanced rigor in technical review and development, with methodology details published independently following peer review. In developing the recommendations, 89 clinical experts and stakeholders participated in an online survey, identifying primary outcomes, such as clinical and endoscopic remission, as well as adverse event metrics, all stratified by clinically relevant effect sizes. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges.